| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.048 | 0.4 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.4 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.13 | 0.4 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |